There's more good news than bad news for this big biotech stock. Vertex Pharmaceuticals (VRTX -20.61%) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday. Were Vertex's Q2 results horrible? Not at all. 1. The bad news wasn't as horrible as the sell-off indicated One of Vertex's pipeline disappointments was that VX-993 didn't meet the primary endpoint in a phase 2 study evaluating the NaV1.8 pain signal inhibitor in treating acu ...